EUVIMEDEUVIMED entdecken
Crossref

Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021

Francisca Abanyie iD, Joanna Ng, Kathrine R Tan

Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e857-e863

DOI: 10.1093/cid/ciac719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 02.09.2022. Verfasst von Francisca Abanyie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Antimalarials, Artemisinins, Malaria, Malaria, Falciparum. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Studies have demonstrated the safety and efficacy of intravenous artesunate (IVAS) for treatment of severe malaria in endemic and nonendemic countries. However, post-artesunate delayed hemolysis (PADH) is an increasingly recognized phenomenon after its administration. This study describes the prevalence and outcomes of PADH events among severe malaria cases treated with IVAS in the United States.

Methods

Patients diagnosed with severe malaria and treated with IVAS from April 2019 to July 2021 were included. Demographic, clinical, laboratory, therapeutic, and outcome measures were described using proportions, medians, and interquartile range. Patients reported to experience PADH were compared with those not reported to have PADH, and tests of significance were performed.

Results

Of 332 patients included in our analysis, 9 (2.7%) experienced PADH. The majority of infections in both groups were in non-Hispanic Black individuals. Parasite density (11.0% vs 8.0%), admission hemoglobin (11.0 g/dL vs 11.8 g/dL) were similar in the 2 groups. Total bilirubin levels at admission (4.7 mg/dL vs 2.2 mg/dL) and within 8 hours after completion of IVAS (2.6 mg/dL vs 1.2 mg/dL) were notably higher in PADH patients. Cumulative IVAS dose of >9.5 mg/kg and >3 doses of IVAS were risk factors for PADH. The majority (7 of 9) of PADH cases were diagnosed within 2 weeks after initiation of IVAS. Five patients (56%) required blood transfusions, and all recovered without sequelae.

Conclusions

PADH is an uncommon and self-limiting adverse event in many cases; weekly monitoring of hemoglobin and hemolytic markers may identify cases requiring intervention in a timely manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsArtemisininsMalariaMalaria, FalciparumHumansUnited StatesArtesunateHemolysis

Stichwörter der Autor:innen

adverse effectsintravenous artesunatepost-artesunate delayed hemolysissafetysevere malaria

Substanzen

ArtesunateAntimalarialsArtemisinins

Autor:innen und Institutionen

  • Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.

ORCID-Profile: Francisca Abanyie

Zitieren

APA

Abanyie, F., Ng, J., & Tan, K. R. (2023). Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021. Clinical Infectious Diseases, 76(3), e857-e863. https://doi.org/10.1093/cid/ciac719

Vancouver

Abanyie F, Ng J, Tan KR. Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021. Clinical Infectious Diseases. 2023;76(3):e857-e863. doi:10.1093/cid/ciac719

BibTeX
@article{Abanyie2023,
  author = {Abanyie, Francisca and Ng, Joanna and Tan, Kathrine R},
  title = {Post-artesunate Delayed Hemolysis in Patients With Severe Malaria in the United States—April 2019 Through July 2021},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {3},
  pages = {e857--e863},
  doi = {10.1093/cid/ciac719}
}
Kostenlos starten →